CLYM - Latest News
Climb Bio, Inc. (CLYM), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $891.9M. Beta to the broader market is 0.10.
The article list below shows the most recent CLYM headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent CLYM Headlines
Why Is Climb Bio Stock Gaining Friday?
benzinga.com - Jun 12, 2026
Climb Bio Inc. (NASDAQ:CLYM) on Thursday shared initial data from its ongoing Phase 1b portion of its Phase 1b/2a study of budoprutug for primary imm
Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
globenewswire.com - Jun 11, 2026
Data demonstrate favorable safety and tolerability profile, robust B-cell depletion, and encouraging platelet responses in heavily pretreated patients
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
globenewswire.com - Jun 5, 2026
Company to share additional CLYM116 clinical data and plans for further development at R&D Spotlight in late summer
Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
globenewswire.com - May 26, 2026
WELLESLEY HILLS, Mass. , May 26, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc.
Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect
marketbeat.com - May 21, 2026
Climb Bio NASDAQ: CLYM outlined its clinical development strategy and upcoming data readouts during a fireside chat at H. C.
How News Affects CLYM Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track CLYM's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked CLYM news questions
- What is the latest CLYM news headline?
- The most recent CLYM headline (Jun 12, 2026) is "Why Is Climb Bio Stock Gaining Friday?". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the CLYM news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What CLYM news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual CLYM options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.